DRTS

SEC filing DRTS Reports Positive Alpha DaRT Pancreatic Cancer Trial Results, 11.2 Months Median Overall Survival in Metastatic Patients, 36% Treatment-Associated Adverse Events

1d ago

SEC filing DRTS Announces Annual General Meeting, Proposals Include Director Re-Elections, Compensation Approvals, Auditor Re-Appointment

14d ago

News Alpha Tau Medical GAAP EPS of -$0.26

14d ago

SEC filing DRTS Reports 100% Local Disease Control, 67% Complete Response Rate in Alpha DaRT Glioblastoma Trial

22d ago

SEC filing DRTS Reports First Italy Pancreatic Cancer Treatment, $15.7K Cases, 11% Survival, Multi-Delivery Trial

26d ago

SEC filing DRTS Announces Alpha DaRT Head Neck Cancer Combo Study Accepted for AHNS Podium Presentation

28d ago

SEC filing DRTS Reports 100% Local Disease Control in Pancreatic Cancer Trials, 27% Device Adverse Events, EUS Integration, First DDW 2026 Presentation

29d ago

SEC filing DRTS Reports $76.9M Cash, FDA Approves Prostate Trial, Launches Skin Cancer Module, Targets 5 U.S. Trials

84d ago

SEC filing DRTS Announces 5 US Trials, Seeks Pancreatic Cancer Data by Q1, GBM Results by Q4

124d ago

News Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

165d ago

News Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference

165d ago